October 28, 2019
Astellas Pharma grabbed European approval for its FLT3/AXL inhibitor treatment Xospata (gilteritinib) for the treatment of acute myeloid leukemia (AML) on October 24, a week after a key panel in the region nixed its rival from Daiichi Sankyo. The European...read more